SCHEMBL855351

SCHEMBL855351

CC(O)c1nc2cc(Br)cnc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
ALDH1A1 P00352 4/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
DYRK1A Q13627 3/20 0.37
ABL1 P00519 3/20 0.37
RET P07949 3/20 0.37
KDR P35968 3/20 0.37
CDK7 P50613 3/20 0.37
CDK5 Q00535 3/20 0.37
PRKAA1 Q13131 3/20 0.37
AURKB Q96GD4 3/20 0.37
CLK4 Q9HAZ1 3/20 0.37
MAPT P10636 2/20 0.37
PAK4 O96013 2/20 0.37
CDK8 P49336 2/20 0.37
AURKA O14965 2/20 0.37
JAK2 O60674 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12309248 0.87 LMNA (0.40) ALDH1A1HTTDYRK1AABL1RET
SCHEMBL13620301 0.77 ALPL (0.37) ALDH1A1KMT2ADYRK1AABL1RET
SCHEMBL29124653 0.76 KDM5A (0.36) CYP1A2MEN1KMT2AABL1RET
SCHEMBL14770725 0.76 MEN1 (0.39) ALDH1A1HTTMEN1KMT2AABL1
SCHEMBL1192302 0.74 SMN1; SMN2 (0.53) ALDH1A1HTTKMT2ADYRK1AABL1
SCHEMBL31588150 0.74 SMN1; SMN2 (0.53) ALDH1A1HTTKMT2ADYRK1AABL1
SCHEMBL12319224 0.74 FGFR1 (0.33) ALDH1A1MEN1KMT2ADYRK1AABL1
SCHEMBL14770635 0.74 DYRK1B (0.38) ALDH1A1HTTABL1RETCDK7
Hydrochloric Acid SCHEMBL4855839 0.73 ALDH1A1 (0.31) ALDH1A1
SCHEMBL6518875 0.72 CYP1A2 (0.44) CYP1A2ALDH1A1ALOX15HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
CN-102459249-A Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases EXELIXIS INC 2012-05-16 CN disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA CYP1A2 997/4885ALDH1A1 3395/4885ALOX15 599/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA CYP1A2 878/4885ALDH1A1 3533/4885ALOX15 585/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA CYP1A2 1244/4885ALDH1A1 3049/4885ALOX15 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.